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INTRODUCTION
The National Comorbidity Survey Replication (NCS-R) in 
the US found that at least 68% of subjects with a psychiatric 
disorder had at least one comorbid general medical condi-
tion (GMC), while 29% of those with a GMC had at least a 
comorbid psychiatric disorder.1 A population study, con-
ducted in Singapore, found that the rate of any physical dis-
order in those with psychiatric disorders was 50.6%.2 Several 
other studies confirmed that psychiatric disorders frequently 
co-occur with GMCs3-5 and this co-occurrence has been par-
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ticularly documented in patients affected by bipolar disorder, 
schizophrenia and depressive disorders.6-8 
The high occurrence of GMCs in patients with mental dis-
orders can be explained in three ways: the impact of psycho-
pharmacological treatments (mainly second-generation anti-
psychotics), illness-related factors such as the adoption of 
unhealthy lifestyles associated with the psychiatric disorder 
itself (i.e., increased caloric intake, cigarette smoking, alcohol 
use and low physical activity), and probably inherited biologi-
cal factors such as hypothalamic pituitary adrenal axis dysreg-
ulation. For example, in a recent review study, Mansur and 
coworkers concluded that obesity and mood disorders are 
intrinsically linked and share a series of clinical, neurobio-
logical, genetic and environmental predisposing factors.9
Several research and review studies evaluated the preva-
lence of GMCs in patients with bipolar disorder or schizo-
phrenia. These patients suffer more frequently from cardio-
vascular diseases, hypertension, diabetes, endocrine diseases 
such as hypo-hyperthyroidism, respiratory diseases such as 
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asthma or chronic obstructive pulmonary illness, liver and/or 
renal conditions, peptic ulcer, and arthritis.10-12
The relationship between anxiety disorders or obsessive-
compulsive spectrum disorders and GMCs is less documented. 
Some studies found significant associations between anxiety 
disorders and cardiac disorders, hypertension, gastrointesti-
nal problems, genitourinary disorders and migraine.13-15 On 
the other hand, clinical studies also suggested that anxiety dis-
orders could be an early manifestation of GMCs.16-18 Only few 
studies investigated prevalence rates of metabolic syndrome 
(MetS) in patients with a primary diagnosis of anxiety disor-
ders; rates of MetS, from 21.2% to 47.8%, are higher than those 
in the general population.19-23 In OCD patients, the long-term 
(1-year) use of antipsychotics added to SRIs has been associ-
ated with an increase in body mass index and fasting blood 
sugar.24 Moreover, the use of a long-term antidepressant ther-
apy (serotonin reuptake inhibitors) is also associated with a 
significant weight gain.25 
Despite the considerable body of research examining GMCs 
in other psychiatric disorders, there is little research examin-
ing the physical health of patients with OCD: as a result, co-
morbid GMCs may be underdiagnosed and undertreated in 
clinical practice in subjects with OCD. 
The aim of this study was to assess the prevalence of GMCs 
in patients with a primary diagnosis of OCD and, secondly, to 
investigate which clinical variables are associated with the pres-
ence of a GMC.
METHODS
Subjects
The study had a naturalistic design and involved patients 
with a primary diagnosis of OCD consecutively admitted to 
the Mood and Anxiety Disorders Unit, Department of Neu-
roscience, University of Turin (Italy) from January 2013 to 
December 2015. This is a tertiary referral center mainly for pa-
tients from Piedmont and Aosta’s Valley regions, located with-
in the University General Hospital, specialized in the treat-
ment of patients with OCD. 
Subjects with a principal diagnosis of OCD according to the 
DSM-IV TR, with a minimum total score of 16 on the Yale-
Brown Obsessive Compulsive Scale (Y-BOCS) and with at 
least 18 years old were included in the study.
Exclusion criteria were: primary diagnosis of schizophrenia, 
schizoaffective disorder, bipolar disorder, delusional disorder, 
severe personality disorders (such as borderline and antiso-
cial), substance use disorders; pregnancy or recently given birth, 
refusal to sign the informed consent before starting the study.
Participants expressed willingness to take part in the study 
by signing a written consent after the aims of the study and 
study procedures were thoroughly explained. All subjects 
were of Caucasian Italian origin. The study design was reviewed 
by the local ethics committee.
Assessments and procedures
Data were obtained through the administration of a semi-
structured interview, used in our previous studies23,25 with a 
format that covered the following areas: socio-demographic 
data, diagnostic evaluation (by means of the Structured Clin-
ical Interview for DSM-IV Axis I and II Disorders), age at on-
set of OCD, duration of untreated illness (DUI), defined as 
time from onset of the disorder to first correct treatment re-
ceived, body mass index (BMI). Lifestyles were also investi-
gated: information about exposure to cigarette smoking and 
physical exercise were obtained by directly interviewing the 
patients. A score was assigned to the frequency of physical ex-
ercise: absent, mild (<4 h/week), moderate (4 h/week with a 
tolerance of ±30 min) and intense (>4 h/week, regular). 
In addition, the following rating scales were included in the 
assessment: Y-BOCS, Hamilton Anxiety Rating Scale (HAM-
A), Hamilton Depression Rating Scale (HAM-D), Clinical 
Global Illness - Severity (CGI-S). 
The inter-rater reliability of DSM-IV diagnoses using the 
SCID-I was tested before the beginning of the study (>0.80 for 
the presence of any lifetime Axis I disorders). Inter-rater reli-
abilities of the Y-BOCS, HAM-A and HAM-D total scores were 
also good (>0.80).
The presence of GMCs was investigated using ICD-10 di-
agnoses; moreover, we grouped GMCs according to the Cu-
mulative Illness Rating Scale (CIRS)26 as follows: cardiac, vas-
cular, hematopoietic, respiratory, ear/nose/throat, upper and 
lower gastrointestinal, hepatic, renal, genitourinary, muscu-
loskeletal, neurologic, and endocrine/metabolic. 
Statistical analysis
All statistical analyses were performed using SPSS version 
20.0 (IBM Corp., Armonk, NY, USA) and the value of statis-
tical significance was set at p<0.05.
The socio-demographic and clinical characteristics of the 
subjects were represented as mean and standard deviation 
(SD) for continuous variables and in terms of frequency and 
percentage regarding categorical variables. GMCs according 
to CIRS system were summarized as percentages. 
The sample was divided in two subgroups according to the 
presence/absence of at least one GMC. In order to analyze 
differences between these two subgroups, we used the Pear-
son χ2 test with Yates correction for the comparison of cate-
gorical variables, and t-test for independent samples for con-
tinuous variables.
A logistic regression analysis was finally used to explore the 
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relationship between the presence of GMCs in patients with 
OCD (dependent variable) and each of the other independent 
variables previously found associated in the statistical analy-
ses. The probability of entering the equation was set at 0.05.
RESULTS
We reported data on 162 patients with a primary diagnosis 
of OCD. We excluded 30 BD or schizophrenia patients with 
comorbid OCD. Other 12 patients were excluded because 
they declined to participate. Lastly, six patients showed a Y-
BOCS total score inferior to 16 after initial assessment and 
therefore they were not considered for this study.
Patients had a mean age of 35.6±14.4 years; 96 (59.3%) 
were males. Mean age at onset of OCD was 19.3±7.3 years, with 
a mean DUI of 115.9±113.6 months. Socio-demographic 
and clinical characteristics of subjects included in the present 
study are summarized in Table 1. 
A total of 78 (48.1%) patients had at least one comorbid 
GMC. Most frequent GMCs were endocrine/metabolic dis-
eases (25.9%), followed by upper/lower gastrointestinal (20.5%) 
and cardio-vascular diseases (13.6%). Among endocrine/met-
abolic diseases, most frequent conditions were hypercholes-
terolemia (n=40, 24.7%), hypo/hyper-thyroidism (n=22, 13.6%), 
ten cases of diabetes mellitus (6.2%) (two insulin-dependent 
diabetes mellitus). Among upper/lower gastrointestinal dis-
eases, most frequent conditions were gastroesophageal reflux 
(n=25, 15.4%), Gilbert’s syndrome (n=10, 6.2%), seven cases 
(4.3%) of chronic intestinal inflammatory diseases and chole-
lithiasis. Lastly, among cardio-vascular disease, most frequent 
conditions were hypertension (n=20, 12.3%), anemia (n=13, 
8.0%), and eight cases (4.9%) of valvular heart diseases. Ac-
cording to NCEP ATP III, 32 patients (19.8%) met the criteria 
for metabolic syndrome.
Regarding pharmacological treatment, the vast majority of 
patients were taking medium-to-high doses of serotonin reup-
take inhibitors (SRIs) according to International guidelines. 
Some patients were taking also low dosage antipsychotics 
(mainly aripiprazole, olanzapine or risperidone) as augmenta-
tion treatment. Table 2 shows current pharmacological treat-
ment of subjects with or without GMC. No significant differ-
ences were found between the two groups. 
When we divided our sample according to the presence/ab-
sence of at least one GMC and compared the two subgroups, 
patients with GMCs were more frequently females (56.4% vs. 
26.2%, p=0.006), were older (42.0±15.4 vs. 29.7±10.6 years, 
p<0.001), had a longer DUI (153.0±134.9 vs. 77.0±80.7 months, 
p=0.003), and had no physical activity (51.3% vs. 76.2%, p=0.019) 
(Table 3).
However, when we performed a stepwise logistic regression 
analysis, the duration of untreated illness no longer predicted 
the presence of a GMC (Table 4).
DISCUSSION
The primary aim of our study was to assess the prevalence 
of GMCs in patients with OCD. The prevalence of at least 
one GMC was 48.1% in our sample, demonstrating the high 
occurrence of physical morbidity in subjects with OCD. Dif-
ferent models have been proposed to explain the high co-oc-
currence of anxiety disorders in general and physical diseases: 
anxiety may be a consequent or antecedent factor of a physi-
cal illness, third variables may lead to the comorbidity or, com-
mon genetic, environmental or personality factors may con-
tribute to the co-occurrence.27 
The most prevalent GMCs were endocrine/metabolic dis-
eases (25.9%) while the prevalence of metabolic syndrome was 
19.8%. This result is in line with our previous study in OCD 
subjects where the MetS prevalence was 21.2%23: to the best 
of our knowledge, no other studies on MetS in OCD patients 
were conducted and, although we could not perform any di-
Table 1. Socio-demographic and clinical characteristics of all sub-
jects included (N=162)
All sample
Male gender, N (%)  96 (59.3) 
Age (years), mean±SD 35.6±14.4
Education (years), mean±SD 12.6±3.7
Marital status, N (%)
Single
Married
Separated 
Widowed
108 (66.7)
44 (27.2)
6 (3.7)
4 (2.4)
Occupational status, N (%)  98 (60.5)
Age at onset (years), mean±SD 19.3±7.3
Duration of untreated illness (months), mean±SD 115.9±113.6
Cigarette smoking, N (%) 40 (24.7)
Physical activity, N (%) 
Absent
Mild
Moderate
Intense
104 (64.2)
58 (35.8)
66 (40.7)
30 (18.5)
8 (4.9)
Yale-Brown Obsessive-Compulsive Scale, mean±SD
Obsession score
Compulsion score
25.6±6.1
12.9±3.1
12.7±3.5
Hamilton Depression Rating Scale, mean±SD 11.7±6.3
Hamilton Anxiety Rating Scale, mean±SD 11.3±5.5
Clinical Global Illness-Severity, mean±SD 3.8±0.9
Body Mass Index, mean±SD 25.7±5.5
SD: standard deviation, N: number
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rect comparison, this prevalence is similar to that observed in 
the Italian general population (16–17.8%). However, the mean 
age of our sample was 35.6 years, and the result of a preva-
lence rate of nearly 20% of MetS in this group is of clinical rel-
evance. The age-adjusted prevalence of MetS in the US gener-
al population is 27.0%,28 while European studies have found 
lower rates, between 8% and 17.8%.29-32 A recent study, con-
ducted on 97 patients with severe OCD, showed a similar prev-
alence of endocrine/metabolic diseases (23.7%).33 
There is a strong association between weight gain, obesity 
or metabolic abnormalities and psychopharmacological treat-
ments, particularly second-generation antipsychotics (i.e. olan-
zapine or asenapine or quetiapine) and antidepressants with 
high H1-histamine receptor affinity (i.e. tricyclics and mirtazap-
ine) due to counteracting the central anorexigenic effects of 
histamine or increasing adipose tissue deposition.34 A meta-
analysis based on 116 studies employing most marketed an-
tidepressants highlighted that different antidepressant medi-
cations greatly differ in affecting body weight. The authors 
found that tricyclics and mirtazapine were associated with the 
maximum weight gain, where most SSRIs, SNRIs and bupro-
pion induced very little, if anything, weight gain.35 On the 
other hand, a systematic review recently highlighted the as-
sociation between use of antidepressants and new onset type 
2 diabetes.36 Together with illness-related factors such as the 
adoption of unhealthy lifestyles and probably inherited bio-
logical factors, specific pharmacological treatments could play 
a significant role in leading to the MetS.34,37-39
Our prevalence rates of cardio-vascular and neurological dis-
eases are comparable of those found in subjects with mental 
disorders by a population study conducted in Singapore.2 De-
spite these similarities, we found lower prevalence rates of car-
dio-vascular, musculoskeletal, respiratory, genitourinary and 
neurological disorders compared to other studies and higher 
prevalence rate on gastrointestinal diseases.33,40 This result 
could be explained by different methodology used and sample 
recruitment: for example, Drummond and coworkers consid-
ered only patients with severe OCD (subjects with severe OCD 
could have more physical burden). 
The prevalence of any GMCs or a specific class of GMCs in 
a sample of subjects with a given psychiatric disorder has to 
be interpreted also comparing these rates with those in other 
psychiatric disorders. 
The relationship between GMCs and major depression dis-
order was investigated in the Sequenced Treatment Alterna-
tives to Relieve Depression (STAR*D) study. The prevalence of 
significant medical comorbidity in this population was 52.8%, 
similar to that found in our OCD population; concurrent GMCs 
Table 2. Pharmacological treatment of patients with OCD with and without GMC
No GMC (N=84) GMC (N=78) t/χ2 p
No treatment, N (%) 14 (16.7) 8 (10.3) 1.416 0.234
At least one SSRI, N (%) 58 (69.0) 60 (76.9) 1.268 0.260
Fluoxetine, N (%) 14 (16.7) 16 (20.5) 0.397 0.529
Mean FLX dose, mean±SD 47.14±9.14 47.50±8.56 -0.110 0.913
Fluvoxamine, N (%) 20 (23.8) 24 (30.8) 0.990 0.320
Mean FLUV dose, mean±SD 255.00±48.40 237.50±47.20 1.211 0.233
Paroxetine, N (%) 12 (14.3) 10 (12.8) 0.074 0.786
Mean PAR dose, mean±SD 46.00±5.16 48.00±7.89 -0.671 0.511
Sertraline, N (%) 12 (14.3) 10 (12.8) 0.074 0.786
Mean SERT dose, mean±SD 179.17±23.44 180.00±25.82 -0.079 0.215
Clomipramine, N (%) 12 (14.3) 10 (12.8) 0.074 0.786
Mean CMI dose, mean±SD 183.33±35.89 190.00 ±26.87 -0.484 0.633
At least one AP, N (%) 20 (23.8) 24 (30.8) 0.990 0.320
Aripiprazole, N (%) 6 (7.1) 8 (10.3) 0.497 0.481
Mean ARI dose, mean±SD 10.00±0.00 11.25±2.32 -1.309 0.215
Risperidone, N (%) 8 (9.5) 8 (10.3) 0.024 0.876
Mean RISP dose, mean±SD 1.50±0.54 2.00±0.76 -1.528 0.149
Olanzapine, N (%) 6 (7.1) 8 (10.3) 0.497 0.481
Mean OLA dose, mean±SD 5.83±1.29 5.63±2.91 0.162 0.874
OCD: Obsessive-Compulsive Disorder, GMC: General Medical Condition, N: number, SD: standard deviation, SSRI: Selective Serotonin 
Reuptake Inhibitor, FLX: fluoxetine, FLUV: fluvoxamine, PAR: paroxetine, SERT: sertraline, CMI: clomipramine, AP: antipsychotic, ARI: ar-
ipiprazole, RISP: risperidone, OLA: olanzapine
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appeared to influence the severity and symptom patterns in 
MDD.41
Compared to depression, the link between anxiety disorders 
and physical health is relatively understudied. Individuals with 
elevated anxiety are more likely than those without anxiety 
to have a wide array of medical conditions, including cardio-
vascular, autoimmune, and neurodegenerative diseases, and 
are at greater risk for early mortality.42 In a large community 
sample (n=42,249), people diagnosed with anxiety disorders 
were more likely to have a variety of medical conditions in-
cluding obesity (OR 1.2), diabetes (OR 1.3), asthma (OR 1.6), 
hypertension (OR 1.7), arthritis (OR 1.7), ulcer (OR 1.9), back/ 
neck problems (OR 2.0), heart disease (OR 2.0), headache (OR 
2.3), and multiple pains (OR 2.3).43 
When examining socio-demographic and clinical character-
istics potentially associated with GMCs in patients with OCD, 
firstly we found a significant association with female gender 
and older age. This result was quite expected: as a matter of fact, 
it is obvious that older age implies higher probability of expe-
riencing GMCs. Moreover, females patients in our sample 
Table 3. Socio-demographic and clinical differences between OCD with/without GMCs
No GMCs (N=84) GMCs (N=78) t/χ2 p
Male gender, N (%) 62 (73.8) 34 (43.6) 7.649 0.006
Age (years), mean±SD 29.7±10.6 42.0±15.4 -4.211 <0.001
Education (years), mean±SD 12.9±3.3 12.4±4.1 0.609 0.156
Marital status, N (%)
Single
Married
Separated 
Widoved
62 (73.8)
18 (21.4)
4 (4.8)
0 (0.0)
46 (59.0)
26 (33.3)
2 (2.6)
4 (5.1)
4.140 0.247
Occupational status, N (%) 58 (69.0) 40 (51.3) 2.671 0.102
Age at onset (years), mean±SD 18.2±7.7 20.5±6.8 -1.432 0.156
Duration of untreated illness (years), mean±SD 77.0±80.7 153.0±134.9 -3.101 0.003
Cigarette smoking, N (%) 22 (26.2) 18 (23.1) 0.105 0.745
Physical activity, N (%)
Absent
Mild
Moderate
Severe
64 (76.2)
20 (23.8)
40 (47.6)
16 (19.0)
8 (9.5)
40 (51.3)
38 (48.7)
26 (33.3)
14 (17.9)
0 (0.0)
5.459 
8.245
0.019
0.041
Y-BOCS, mean±SD
Obsession score
Compulsion score
26.3±6.2
13.2±3.2
13.1±3.5
24.9±6.0
12.7±2.9
12.2±3.6
1.044
0.733
1.166
0.299
0.465
0.247
Hamilton Depression Rating Scale, mean±SD 11.7±5.9 11.8±6.8 -0.073 0.942
Hamilton Anxiety Rating Scale, mean±SD 11.2±5.5 11.5±5.6 -0.281 0.780
Clinical Global Illness-Severity, mean±SD 3.8±0.9 3.8±0.9 -0.036 0.971
Body Mass Index, mean±SD 25.4±4.9 26.0±6.1 -0.532 0.596
OCD: Obsessive-Compulsive Disorder, GMC: General Medical Condition, N: number, SD: standard deviation, Y-BOCS: Yale-Brown Obses-
sive Compulsive Scale
Table 4. Relationship between potential explanatory variables and presence of GMCs in patients with OCD: results from the stepwise logis-
tic regression analysis
Step Variables T E.S. Wald df p Exp (B) 95% CI for EXP
Step 1 Gender -0.842 0.391 4.627 1 0.031 0.431 0.200–0.928
Step 2 Age 0.058 0.017 11.780 1 0.001 1.059 1.025–1.095
Step 3 Duration of untreated illness 0.002 0.002 0.693 1 0.405 1.002 0.998–1.006
Step 4 Physical activity 1.306 0.395 10.952 1 0.001 3.693 1.704–8.007
Constant -2.290 0.678 11.404 1 0.001 0.101
OCD: Obsessive-Compulsive Disorder, GMC: General Medical Condition
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were older than males, although this difference was not sta-
tistically significant (data not shown), and this might in part 
explain the association between female gender and higher 
rate of GMCs. As we did not include a comparison group 
without OCD (e.g., from the general population), we cannot 
conclude that OCD is per se at higher risk of having a GMC 
beyond the effect of age. However, we do think that clinicians 
should be aware that approximately half of OCD patients do 
display a comorbid GMC that needs careful examination and 
treatment. 
Secondly, patients with OCD and comorbid GMCs showed 
a higher DUI. To the best our knowledge, this is the first study 
to find an association between a longer DUI and the pres-
ence of GMCs in patients with OCD. Although this issue has 
been adequately studied in patients with schizophrenia and 
bipolar disorder, to date, only few studies showed the nega-
tive impact of a longer DUI in OCD. In previous studies, a lon-
ger DUI was significantly associated with poor treatment re-
sponse (DUI >24 months),44 specific obsessive-compulsive 
dimensions (aggressive/checking dimension),45 older age, early 
age at onset, and older age of first pharmacological treatment 
(DUI >4 years). A shorter DUI (<4 years) was associated with 
abrupt onset of OCD, precipitated by life events.46 Although 
the longer DUI no longer predicted the presence of a GMC in 
the logistic regression analysis, we consider our results worth 
to be discussed; it is possible that subjects not appropriately 
treated for years (longer DUI) display unhealthy lifestyles, or 
have poor access to the healthcare system even for general 
medical conditions or medical complications of severe OC 
symptoms (e.g., excessive hand or body washing leading to 
dermatological problems, avoidance of medical consulta-
tions for fear of contamination leading to failure to get ap-
propriate diagnosis and treatment of an independent medi-
cal problem). Another explanation is based on alteration of 
hormonal system due to higher levels of stress that lead to an 
increase in cortisol levels and consequently poor glucose tol-
erance and obesity, diabetes, and hypertension. This in turn 
might lead to an increased risk to develop some GMCs, es-
pecially endocrine and cardiovascular diseases. 
Lastly, GMCs in patients with OCD were significantly as-
sociated with the absence of physical activity. In our sample, 
fifty-eight patients (35.8%) did not engage in any physical ac-
tivity. It is known that a lack of physical activity is associated 
with anxiety disorders while physical inactivity is associated 
with many chronic physical diseases,47-49 It could be suggest-
ed that subjects with OCD are at increased risk to develop 
GMCs at least in part through physical inactivity. 
The benefits of physical activity are well known and are 
summarized as follows: it promotes fat oxidation reducing 
the risk of obesity (important cardio-vascular risk factor and 
core component of MetS), improves insulin sensitivity thus 
reducing the risk of type 2 diabetes, prevents hypercholester-
olemia and/or hypertension reducing the risk of heart dis-
ease or several cancers or premature death caused by heart 
attacks, decreases, in particular among children and young 
people, risky behaviors such as use of tobacco or alcohol, un-
healthy diets, eases anxiety management and stressful situa-
tions, reduces the risk of osteoporosis and fractures but also 
musculoskeletal disorders (e.g., back pain). In the general 
population, physical activity has been shown to be the optimal 
strategy to improve both cardio-metabolic parameters and 
cardiorespiratory fitness levels. Psychoeducational programs 
are well structured in patients with bipolar disorder and schizo-
phrenia.50-53 The improvement of anxiety symptoms due to 
physical activity has been studied in patients with anxiety 
disorders54: in our opinion, these programs should be tested 
also in patients with OCD to see whether MetS could be pre-
vented.
Obviously, the impact of GMCs associated with OCD is in-
tuitively relevant for several reasons such as a worsened quali-
ty of life and functioning, an higher utilization of healthcare 
resources, and an increased risk of hospitalization and mor-
tality: this supports the need for a proper functioning of health-
care integrated system. A recent population study conducted 
by Witthauer and coworkers on 4,181 subjects (aged 18–65), 
evaluated the association between GMCs and subjects with 
clinical and subthreshold OCD. The authors reported that sub-
jects with both OC symptoms and GMCs reported the high-
est number of days of disability due to physical or psycholog-
ical problems during the past 30 days compared to subjects 
with only OC symptoms, only GMC or neither of them.40 Less 
access to care, a no integrated health care system, patient dif-
ficulties to clearly describe medical symptoms, and patient 
shame feelings to discuss some clinical features lead to less 
attention in the fully evaluation and management of GMC in 
patients with major psychiatric disorders such as bipolar dis-
order and schizophrenia.55-57 
The reader should be mindful of a number of limitations in 
the current study when interpreting our findings. The first one 
is the cross-sectional design that does not allow inferences 
on the temporal relationship between the variables and only 
shows measures of association. Secondly, the lack of a control 
group from another psychiatric population or the general 
Italian population. Another limitation is the small sample 
size recruited for the present study. However, our aim was to 
look for significant correlations between the presence of GMCs 
and clinical variables in patients with OCD, and therefore, an 
healthy group was not needed. 
In conclusion, this study emphasizes the need to ensure 
that GMCs are not overlooked in psychiatric patients in gen-
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eral and in subjects with OCD in particular. We cannot con-
clude that the prevalence of GMCs is higher in OCD patients 
as compared to the Italian general population, but the rate of 
48.1% in a sample with a mean age of 35.6 years is, to our 
opinion, clinically relevant. Assessment plus management of 
GMCs in patients with OCD are basic clinical factors in achiev-
ing satisfactory medical and psychiatric outcomes, in terms 
of stability, treatment adherence, life expectancy as well as 
quality of life, of these generally disadvantaged populations 
worldwide. Therefore, all patients should receive adequate eval-
uation and surveillance of GMCs and this process should be 
particularly made when patients with OCD are treated with 
second-generation antipsychotics as augmentation to anti-
obsessive medications. It might help clinicians and general 
practitioners to be sensitized for a better dissemination of in-
tegrated care system in order to recognize and to accomplish 
secondary prevention of potentially severe medical compli-
cations.
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